| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30058638 | HIV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
| TVIS30020716 | HIV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
| TVIS30058639 | HIV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
| TVIS20036587 | HPV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
| TVIS20023553 | HPV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | P2RY12 |
|---|---|
| DrugBank ID | DB00758 |
| Drug Name | Clopidogrel |
| Target ID | BE0000110 |
| UniProt ID | Q9H244 |
| Regulation Type | antagonist |
| PubMed IDs | 14668029; 15199474; 15269827; 15291969; 15308557; 19463375; 16835302; 12615691 |
| Citations | Dorsam RT, Murugappan S, Ding Z, Kunapuli SP: Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology. 2003 Dec;8(6):359-65.@@Herbert JM, Savi P: P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.@@Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schomig A, Schomig E: Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004 Aug;92(2):311-6.@@Wang L, Jacobsen SE, Bengtsson A, Erlinge D: P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 2004 Aug 3;5:16.@@Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D: ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1810-5. Epub 2004 Aug 12.@@Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008.@@Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, Herbert JM: The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11069-74. Epub 2006 Jul 11.@@van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG: In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):518-23. Epub 2003 Jan 23. |
| Groups | Approved |
| Direct Classification | Alpha amino acid esters |
| SMILES | [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl |
| Pathways | Clopidogrel Action Pathway; Clopidogrel Metabolism Pathway |
| PharmGKB | PA449053 |
| ChEMBL | CHEMBL1771 |
